Biocept Announces Issuance of South Korean Patent Covering its Target Selector™ Oncogene Mutation Enrichment and Detection Platform
"The issuance of this patent further expands
"Expanding U.S. and international patent protection for our Target Selector™ liquid biopsy platform is an important strategic focus as we seek to expand our global business through the sale of assays performed at
About
The Switch-Blocker technology covered by South Korean Patent No. 2010601 further expands on U.S. Patent No. 9,834,817, European Patent No. 2,705,162, Chinese Patent No. ZL201280032293.0, Japanese Patent No. 6404118, and Australian Patent No. 2012250516, which are applicable to a broad range of molecular genomic platforms, including real-time PCR, digital PCR,
About
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. To the extent that statements in this release are not strictly historical, including, without limitation, statements as to our ability to expand our business globally and expand the adoption of our tests, and the ability of our tests to provide clinically actionable information to oncologist and their patients, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous risk factors as set forth in our
Contact:
LHA Investor Relations
Jcain@lhai.com
310-691-7100
View original content to download multimedia:http://www.prnewswire.com/news-releases/biocept-announces-issuance-of-south-korean-patent-covering-its-target-selector-oncogene-mutation-enrichment-and-detection-platform-300930255.html
SOURCE